Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04463615 · ClinicalTrials.gov registry record · Phase 2
Leflunomide for the Treatment of Relapsed or Refractory CD30+ Lymphoproliferative Disorders
A Phase 2 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT04463615 is a Phase 2 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 1 participants.
The verdict
NCT04463615, a Phase 2 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This trial studies how well leflunomide works for the treatment of patients with CD30+ lymphoproliferative disorders that have come back (relapsed) or do not respond to treatment (refractory). Leflunomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG Leflunomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2021-05-05 |
| Est. Completion | 2021-07-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04463615
The ClinicalTrials.gov registry entry for NCT04463615 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Leflunomide is the first listed.
NCT04463615 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04463615 about?
NCT04463615 is a clinical study titled "Leflunomide for the Treatment of Relapsed or Refractory CD30+ Lymphoproliferative Disorders". This trial studies how well leflunomide works for the treatment of patients with CD30+ lymphoproliferative disorders that have come back (relapsed) or do not respond to treatment (refractory). Leflunomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT04463615?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2021-05-05. Estimated completion is 2021-07-28.
What interventions are being tested in trial NCT04463615?
The interventions under investigation include: Leflunomide (DRUG).
Who is sponsoring clinical trial NCT04463615?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.